Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Overview Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Companies Involved in Therapeutics Development Allinky Biopharma Array BioPharma Inc AstraZeneca Plc Chiesi Farmaceutici SpA Eli Lilly and Co GlaxoSmithKline Plc Synovo GmbH TopiVert Ltd Zocere Inc Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Drug Profiles AIK-3a - Drug Profile Product Description Mechanism Of Action R&D Progress ARRY-797 - Drug Profile Product Description Mechanism Of Action R&D Progress CHF-6297 - Drug Profile Product Description Mechanism Of Action R&D Progress losmapimod - Drug Profile Product Description Mechanism Of Action R&D Progress neflamapimod - Drug Profile Product Description Mechanism Of Action R&D Progress pamapimod - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides to Inhibit MAPK14 and MAPK11 for Rheumatoid Arthritis, Multiple Sclerosis and Pancreatic Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress ralimetinib mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptide to Inhibit MAPK14 for Ischemic Stroke - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit p38alpha MAP Kinase for Chronic Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress SYD-003 - Drug Profile Product Description Mechanism Of Action R&D Progress TOP-1210 - Drug Profile Product Description Mechanism Of Action R&D Progress Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Dormant Products Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Discontinued Products Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Product Development Milestones Featured News & Press Releases Jul 18, 2017: EIP Pharma announces presentation of new positive clinical data with neflamapimod at Alzheimer's Association International Conference Dec 08, 2016: EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer’s Disease Nov 16, 2016: EIP Pharma announces upcoming oral presentations of Phase 2a clinical trial results with neflamapimod (VX-745) at Clinical Trials in Alzheimer's Disease (CTAD) conference Dec 8-10, 2016 Sep 28, 2016: EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimers disease and ischemic stroke recovery Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress Aug 20, 2016: Array BioPharma Announces Clinical Data Presentation On ARRY-797 At The 2016 European Society Of Cardiology Congress Dec 16, 2015: EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor Oct 27, 2015: GSK provides update on LATITUDE-TIMI 60 (losmapimod cardiovascular study) Jul 15, 2015: Zocere's Brain Saving” Drug Issued U.S. Patent Jun 03, 2015: EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease Jan 07, 2015: Zocere to Present Brain-Protecting Drug at Biotech Showcase Oct 14, 2014: Zocere Showcases “Brain Saving” Drug at Life Sciences Summit in New York City Oct 01, 2014: Zocere’s Stroke Drug to Be Featured at BIO Investor Forum Sep 23, 2014: Public summary of opinion on orphan designation Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Allinky Biopharma, H2 2017 Pipeline by Array BioPharma Inc, H2 2017 Pipeline by AstraZeneca Plc, H2 2017 Pipeline by Chiesi Farmaceutici SpA, H2 2017 Pipeline by Eli Lilly and Co, H2 2017 Pipeline by GlaxoSmithKline Plc, H2 2017 Pipeline by Synovo GmbH, H2 2017 Pipeline by TopiVert Ltd, H2 2017 Pipeline by Zocere Inc, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Dormant Products, H2 2017 (Contd..2), H2 2017 Dormant Products, H2 2017 (Contd..3), H2 2017 Discontinued Products, H2 2017 Discontinued Products, H2 2017 (Contd..1), H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

Allinky Biopharma Array BioPharma Inc AstraZeneca Plc Chiesi Farmaceutici SpA Eli Lilly and Co GlaxoSmithKline Plc Synovo GmbH TopiVert Ltd Zocere Inc